CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Catherine Adams

Chief Executive Officer & Director, Acadia Pharmaceuticals Inc.

Search every verified Catherine Adams interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Catherine Owen Adams, CEO of Acadia Pharmaceuticals, discussed the company’s focus on neuroscience and rare diseases in recent interviews. She highlighted Acadia’s commercial products, including Nuplazid for hallucinations and delusions associated with Parkinson’s disease and Daybue for Rett syndrome, as well as a pipeline of new therapies. Adams noted the company’s strong balance sheet and cash flow, and expressed interest in growth through mergers and acquisitions. Adams addressed the impact of U.S. government funding cuts on biomedical research, stating that while Acadia has not yet felt direct effects, she worries about long-term consequences for smaller biotechs that rely on academic research. She described efforts to engage with policymakers through industry groups, advocating for policies that support small biotech innovation while acknowledging pressures on healthcare costs globally. Adams also discussed the importance of patient support services and collaboration with patient advocacy organizations in developing treatments for rare diseases.

Recent appearances

  • Acadia Pharmaceuticals CEO says she's worried about NIH cuts for the long-term

    January 12, 2026 · 📺 Bloomberg Podcasts

    Catherine Owen Adams, Acadia Pharmaceuticals CEO speaks with Tim Stenovec and Emily Graffeo about Acadia delivering first & only FDA-approved Parkinson's drug. She discussed the climate for biotech innovation and creation of drugs for rare diseases. The NIH has abruptly terminated federally funded critical trials in 2025. The cancellations mark the most extensive disruption to federally funded medical research in modern history, halting studies across every major disease area and undermining the stability of a $48 billion-a-year system that underpins global biomedical innovation. Researchers…

    Watch on YouTube ↗

  • JP Morgan Week 2025 – Catherine Owen Adams

    February 19, 2025 · 📺 pharmaphorum media limited

    The last few years at JP Morgan there’s been a consensus that the neurological disease space is one to watch, as new treatments have changed the game in conditions like Alzheimer’s and Parkinson’s. At this year’s conference, pharmaphorum Editor in Chief Jonah Comstock caught up with Catherine Owen Adams, the CEO of Acadia Pharmaceuticals, to talk about her company’s offerings, including Nuplazid, the only approved medication for treating the hallucinations and delusions associated with Parkinson’s disease. They discuss why it’s so important to treat these symptoms and to raise public awarene…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →